This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Evotec Q1 2013: Driving Innovation Efficiency


HAMBURG, Germany, May 14, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today reported financial results and corporate updates for the first quarter of 2013.
  • Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012
  • Q1 2013 revenues amounted to € 17.1 m (2012: € 20.1 m); up 5% compared to Q1 2012 revenues of € 16.2 m on a like-for-like basis
  • Operating loss at € 2.7 m due to absence of milestone revenues
  • Strong liquidity position at € 60.4 m
  • High and stable equity ratio at 67.3%
  • Good progress in EVT Execute business and EVT Integrate/EVT Innovate alliances
  • Extension of alliance with Genentech validates Evotec's technology platform and broad expertise in drug discovery (after period-end)
  • Important strategic expansion of EVT Execute compound management capability (after-period end)
  • Increase in revenues driven by integrated alliances
  • New alliances with Yale University (December 2012) and Belfer Institute (after period-end) accelerate innovation strategy                                                                
  • New project to fuel future EVT Innovate collaborations: Co-development agreement with Apeiron Biologics AG
  • Significant clinical datapoints ahead in 2013 /2014                                     
  • New hormone identified to treat diabetes as part of Evotec's Cure Beta initiative (after period-end)
  • Start of integration of CCS Cell Culture Service GmbH - Strengthening Evotec's screening capabilities
  • Financial guidance for 2013 confirmed
  • Revenues are expected to grow to a level between € 90 -100 m
  • Operating result before impairment and changes in contingent consideration, if any, is expected to improve over 2012
  • R&D expenditure is expected to be around € 10 m in 2013
  • Strong liquidity position above € 60 m

1. Operational performance 

Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012

Reported Group revenues for the first three months of 2013 decreased by 15% to € 17.1 m (2012: € 20.1 m). Revenues for the first three months of the previous year included a milestone earned in Evotec's development partnership with Andromeda/Teva with DiaPep277® (€ 3.9 m). Excluding milestones, Evotec's revenues for the first quarter 2013 would have increased by 5% over the same period of the previous year. This growth was driven by an increase in revenues within the Company's drug discovery alliances and from new integrated collaborations such as the Cure Beta partnership with Janssen Pharmaceuticals ("Janssen") and the multi-target alliance with Bayer entered into in the second half of 2012. As anticipated, the absence of milestones resulted in an operating loss for the first quarter of 2013 of € 2.7 m. As stated before, the operating result of Evotec may vary significantly between quarters as a result of the timing of performance-based milestone payments and partnering events.

Overall, the Company is on track to achieve increased full-year profitability over 2012 (before impairment and changes in contingent consideration, if any). Liquidity including cash, cash equivalents and investments at the end of March remained strong at € 60.4 m.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.13 -1.20%
FB $118.77 0.81%
GOOG $705.95 0.64%
TSLA $212.66 0.53%
YHOO $36.81 -0.35%


Chart of I:DJI
DOW 17,640.85 -19.86 -0.11%
S&P 500 2,047.12 -3.51 -0.17%
NASDAQ 4,699.2780 -17.8160 -0.38%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs